Dr Bill Love speaks to Proactive Investors about how Destiny Pharma is addressing the Global threat of superbugs and AMR

AMR is associated with the deaths of five million people worldwide each year.  It has been estimated that, by 2050, the global death toll from AMR will rise to 10 million per year.

Destiny Pharma’s Chief Scientific Officer, Dr Bill Love, speaks to Proactive Investors about how Destiny is addressing the global threat of superbugs and AMR.  Click here for the full interview.